文献速递脊柱关节炎

古塞奇尤单抗在活动性银屑病关节炎且TNF抑制剂应答不佳患者中持续应答与基线特征无关:3b期COSMOS临床试验结果

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.
PubMed 文献 · RMD Open · 2024-12-12

COSMOS 3b期试验纳入活动性银屑病关节炎且TNF抑制剂应答不佳患者,随机2:1接受古塞奇尤单抗100 mg或安慰剂。第24周古塞奇尤单抗组ACR20应答率50% vs 安慰剂组28%,ACR50为23% vs 8%,各基线亚组均可见获益。第48周大多数亚组应答率升高或维持。

要点

  • 古塞奇尤单抗100 mg每8周一次,在TNF抑制剂应答不佳的银屑病关节炎患者中第24周ACR20应答率50% vs 安慰剂28%。
  • 第24周ACR50应答率古塞奇尤单抗组23% vs 安慰剂组8%,各基线定义亚组内均观察到古塞奇尤单抗优于安慰剂。
  • 第24周至第48周,古塞奇尤单抗组在几乎所有亚组中应答率升高,多数亚组应答持续。

核心结论

  • 古塞奇尤单抗每8周一次在TNF抑制剂应答不佳的活动性银屑病关节炎患者中,第24周关节、皮肤、患者报告结局和复合结局较安慰剂一致改善,且跨越不同基线定义亚组。
  • 第48周时大多数亚组应答率升高或维持不变。

研究设计与样本

  • 3b期COSMOS试验,活动性银屑病关节炎(压痛关节数和肿胀关节数均≥3)且TNF抑制剂应答不佳患者随机2:1接受古塞奇尤单抗100 mg(第0周、第4周,之后每8周至第44周)或安慰剂(第16周早期逃逸或第24周计划交叉至古塞奇尤单抗100 mg)。
  • 古塞奇尤单抗组n=189,安慰剂组n=96;按基线人口学、疾病特征及既往/ ongoing治疗定义亚组,结果仅作描述性分析。

主要发现

  • 第24周ACR20应答率古塞奇尤单抗组50% vs 安慰剂组28%(主要终点),ACR50应答率23% vs 8%,各亚组内均观察到古塞奇尤单抗优于安慰剂。
  • 第24周至第48周,古塞奇尤单抗组在几乎所有亚组中应答率升高,各种临床结局在第24周及至第48周呈现相似应答模式。

关键数值与推荐

  • ACR20应答率:古塞奇尤单抗组50% vs 安慰剂组28%(第24周,主要终点)。
  • ACR50应答率:古塞奇尤单抗组23% vs 安慰剂组8%(第24周)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase 3b COSMOS trial. Subgroups were defined by baseline demographics, disease characteristics and prior/ongoing therapies. METHODS: Patients with active PsA (tender joint count (TJC) and swollen joint count (SJC) both ≥3) and TNFi-IR were randomised 2:1 to receive guselkumab 100 mg at week 0, week 4, then every 8 weeks through week 44 or to placebo with cross-over to guselkumab 100 mg at week 16 (early escape) or week 24 (planned). Guselkumab effect on joints (American College of Rheumatology (ACR) 20/50/70, enthesitis, dactylitis), skin (Psoriasis Area and Severity Index 90/100, Investigator's Global Assessment 0/1), patient-reported outcomes (PROs) (Functional Assessment of Chronic Illness Therapy-Fatigue, Health Assessment Questionnaire-Disability Index) and composite outcome measures (PsA Disease Activity Score low disease activity, minimal disease activity) were evaluated by baseline patient age, sex, body mass index, SJC, TJC, PsA duration, %body surface area, C reactive protein, pain Visual Analogue Scale, number of prior TNFi and discontinuation reason, and conventional synthetic disease-modifying antirheumatic drug status. Results are descriptive only. RESULTS: Baseline characteristics were similar between guselkumab (n=189) and placebo (n=96) groups. The benefit of guselkumab over placebo in achieving ACR 20 (primary endpoint; 50% vs 28%) and ACR 50 (23% vs 8%) response at week 24 was observed within all subgroups. Furthermore, response rates in the guselkumab group increased between week 24 and week 48 within almost all subgroups. Similar response patterns at week 24 and through week 48 were observed across various clinical outcomes. CONCLUSIONS: Guselkumab every 8 weeks led to consistent improvements through week 24 in joint, skin, PRO and composite outcomes versus placebo across diverse baseline-defined subgroups of TNFi-IR patients with PsA. Response rates increased or were durable through week 48 within most subgroups.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. McInnes IB, Sewerin P, Sharaf M, et al. Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial. RMD Open. 2024. PMID: 39672591. doi:10.1136/rmdopen-2024-004494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。